NMN vs. NR vs. Plain Vitamin B3: The First Head-to-Head Human Trial on NAD+ Boosters
Summary
If you've ever stood in front of a shelf of NAD+ boosters wondering whether NMN, NR, or plain nicotinamide (a cheap form of vitamin B3) actually does anything, this new Nature Metabolism study (published January 2026) is the most useful data point yet. It's the first trial to test all three popular precursors against each other and a placebo in the same people, under the same conditions.
Researchers at Nestlé Research randomized 65 healthy adults (ages 18–50, roughly evenly split by sex) into four groups: nicotinamide riboside (NR, 1,000 mg/day — the form sold as Tru Niagen), nicotinamide mononucleotide (NMN, 1,000 mg/day), nicotinamide (Nam, 500 mg/day — the vitamin B3 form found in many multivitamins), or a placebo. Everyone took their assigned pill daily for 14 days, with blood and urine tested at the start and end, plus detailed 4-hour blood draws after the first and last doses to see acute effects. It was open-label (participants knew what they were taking), though the lab staff analyzing the samples were kept blind to group assignment.
The headline result: NR and NMN each roughly doubled whole-blood baseline NAD+ levels after two weeks (a jump of about 49 µM over placebo), while plain nicotinamide did not raise resting NAD+ at all — it only produced a brief spike for a few hours right after each dose, then faded. This confirms, in humans, something researchers had only seen in mice: NR and NMN aren't absorbed intact and don't directly boost blood NAD+ the way you'd expect. Instead, the study's follow-up experiments — fermenting the compounds with human gut bacteria, and incubating them separately in whole blood — show that gut microbes break down NR and NMN into nicotinic acid (NA, a related B3 form), which is what actually gets converted into NAD+ efficiently once it reaches the bloodstream. Nicotinamide, by contrast, gets absorbed quickly in its original form and works through a different, more limited pathway, explaining its short-lived effect.
A bonus finding: NR and NMN also fed the gut microbiome itself, boosting bacterial growth and short-chain fatty acid (SCFA) production — a marker of gut health — consistently across healthy, older, and even Crohn's disease donor samples in lab dishes. All three supplements were well tolerated, with only one mild, possibly related side effect per active group (hypotension with NR, headache with NMN) out of 65 participants.
Sources: Nature Metabolism, nmn.com summary
What This Means For You
If your goal is a sustained rise in circulating NAD+, this trial suggests NR and NMN at roughly 1,000 mg/day are meaningfully more effective than plain nicotinamide (niacinamide) at 500 mg/day — despite nicotinamide being far cheaper and already present in many standard multivitamins. If you're taking a multivitamin for "NAD+ support" that relies on niacinamide alone, this data suggests it likely won't move your baseline NAD+ much, even though it produces a short-lived bump right after you take it.
Because the mechanism appears to run through gut bacteria converting NR/NMN into nicotinic acid, taking these supplements consistently (not just occasionally) matters more than precise timing relative to meals — the study simply had people take their dose with breakfast for consistency. It also means anything that disrupts your gut microbiome (recent antibiotic courses, significant GI illness) could plausibly blunt the effect, though this wasn't directly tested in people.
The added finding that NR/NMN increase SCFA production and bacterial growth in lab fermentation experiments (across healthy, older, and Crohn's-disease donor samples) hints at a secondary gut-health benefit independent of NAD+ — though this was shown in fermentation dishes, not confirmed as a clinical outcome in the trial participants themselves.
Who might benefit most: healthy adults specifically seeking to raise systemic NAD+ (a biomarker linked to cellular energy metabolism and studied in aging research), not necessarily those seeking specific symptom relief, since no functional outcome (energy, cognition, exercise capacity) was measured here. People on anticoagulants, bile acid sequestrants, or tetracycline antibiotics were excluded from this trial and should check with a doctor before starting any of these, since interactions weren't tested. NMN's regulatory status also varies by country (it has faced scrutiny as an unapproved drug ingredient in some markets), so check local rules before buying.
Important Considerations
This was a short trial — only 14 days — measuring a biomarker (blood NAD+ concentration), not health outcomes like energy, cognitive function, muscle performance, or longevity. A doubled NAD+ reading doesn't automatically translate into a felt benefit, and no outcome of that kind was assessed here.
The design was open-label: participants knew which product they were taking, which could shape self-reported experiences (though the primary NAD+ measurements were done via objective mass spectrometry by analysts blinded to group assignment, limiting bias on the main result). Sample sizes were modest — 15 to 17 people per arm — and everyone was young-to-middle-aged (18–50) and healthy, with normal BMI. Results may not generalize to older adults, people with metabolic disease, or those with existing low NAD+ from illness; the study explicitly raised NAD+ above already-normal levels in healthy people, and the authors note that restoring NAD+ toward normal in a disease population needs separate study.
The proposed gut-microbiome mechanism, while well-supported by ex vivo fermentation and whole-blood experiments, wasn't directly confirmed in participants' own gut samples — no stool samples were collected during the clinical trial itself, so the "your gut bacteria are doing this" story, while compelling, is inferred rather than directly observed in vivo.
Finally, this research was conducted by Nestlé Research (a commercial food/nutrition company), which is worth factoring in when weighing the framing of results, even though the methodology and statistical approach appear rigorous. Be skeptical of any product marketing that cites this study to claim proven anti-aging or longevity benefits — the trial measured a blood biomarker over two weeks, not aging itself.
Terms Explained
Technical Study Details
Study Design
Total Score
JADAD Quality Assessment評価詳細
Randomization
0 / 2Blinding
-1 / 2Dropouts/Withdrawals
1 / 1Study Population
- Healthy male or female aged 18 to 50 years at enrolment
- BMI between 18.5 and 27.0 kg/m^2
Interventions
Placebo (microcrystalline cellulose)
ControlNicotinamide (Nam)
TreatmentNicotinamide riboside (NR)
TreatmentNicotinamide mononucleotide (NMN)
TreatmentOutcomes
| Outcome | Type | Effect | p-value |
|---|---|---|---|
| Whole-blood baseline NAD+ concentration, chronic change | Primary | 49.40 (39.50-59.30) | -Significant |
| Acute (4-h) whole-blood NAD+ metabolome response (iAUC) | Secondary | - | - |
| Chronic (Day 1 to Day 14) whole-blood NAD+ metabolome change (non-NAD+ metabolites: MeNam, MeXPY, NR, NMN, Nam, NAAD) | Secondary | - | - |
| NAD+ metabolome in plasma and urine | Secondary | - | - |
| Targeted plasma amino acids and untargeted whole-blood metabolomics | Secondary | - | - |
| Plasma homocysteine and cysteine response | Secondary | - | P < 0.005Significant |
| Adverse events with probable relation to the study product | Secondary | - | - |
Safety
Conclusion
This head-to-head comparison of three NAD+ precursors in 65 healthy adults (modified ITT) shows that nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), but not nicotinamide (Nam), comparably and significantly increase baseline whole-blood NAD+ concentrations (~2-fold) after 14 days of daily supplementation, whereas Nam only produces an acute, transient effect on the NAD+ metabolome. Complementary ex vivo human microbiota fermentation and whole-blood experiments indicate that NR and NMN are not directly absorbed but are metabolized by gut microbiota to nicotinic acid (NA), a potent NAD+ precursor via the Preiss-Handler pathway, while rapidly absorbed Nam acts acutely via the salvage pathway. NR and NMN (together with NA) also induced beneficial microbial metabolic adaptations (increased growth, SCFA production) across healthy, older, and Crohn's disease donor microbiota. These findings support a gut-dependent, dual-benefit model for NR and NMN: sustained systemic NAD+ elevation together with potential modulation of gut health.Limitations
- The ex vivo whole-blood experiments could not capture the mild acute impact of Nam on the NAD+ metabolome observed in vivo, possibly because isolated whole blood does not entirely reflect the in vivo situation where Nam-derived degradation metabolites may additionally affect NAD+.
- Increased NA concentrations were not detected in venous whole-blood samples from the clinical study despite ex vivo evidence that NA is a potent NAD+ booster, presumably due to NA's slow release, rapid uptake and subsequent metabolism to NAD+.
- Stool samples were not collected in the clinical study, limiting confirmation of microbial deamidation reaction rates and intestinal precursor concentrations in vivo.
- The study was performed only in a healthy population in whom NAD+ concentrations were raised above normal values; further studies are needed to evaluate restoring NAD+ to normal concentrations in a disease population.
- Shallow shotgun sequencing in the ex vivo fermentation study provided limited sequencing depth, reducing sensitivity for low-abundance taxa and precluding functional analysis of specific genes.
- Contrary to prior mouse models, the human study did not recapitulate acute NR/NMN-induced changes in circulating Nam and NA, possibly due to different precursor dosages and differential absorption, potentially affected by the standardized breakfast used in the trial.
- Enterohepatic circulation of Nam could not be ruled out as liver metabolism or bile was not assessed.